CT/NG Testing Market Analysis
The global CT/NG testing market is experiencing significant momentum, with the market size estimated at USD 1.60 billion in 2024 and projected to expand to USD 2.67 billion by 2032. This represents a compound annual growth rate (CAGR) of 6.62% from 2025 to 2032. The upward trajectory of this market is attributed to the rising global burden of sexually transmitted infections (STIs), advancements in molecular diagnostics such as nucleic acid amplification tests (NAATs), and expanding government-supported screening initiatives.
Increasing Global STI Incidence Driving Market Demand
A key growth driver in the CT/NG testing market is the escalating incidence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections. Often asymptomatic, these infections can lead to severe complications like infertility, ectopic pregnancies, and pelvic inflammatory disease if left undiagnosed and untreated. According to recent meta-analyses, the global prevalence of chlamydia and gonorrhea among adults aged 15–49 is approximately 9.9% and 7.2%, respectively, underscoring the urgency for early detection through reliable testing methods.
Get a Free Sample Report of CT/NG Testing Market @ https://www.snsinsider.com/sample-request/7454
In the United States alone, chlamydia and gonorrhea remain the most commonly reported STIs, with 1.6 million and 601,319 cases respectively in 2023. This increasing disease burden has elevated the importance of accurate diagnostic methods, pushing demand for CT/NG testing services across healthcare systems globally.
Government-Supported Screening Programs Catalyzing Market Growth
Public health agencies and governments worldwide have prioritized STI containment through national screening programs, educational campaigns, and testing subsidies. In the U.S., for example, the CDC’s National Chlamydia Screening Program has contributed to a dramatic rise in annual testing rates among sexually active women aged 16–24, with a 111% increase reported among commercial HMOs since 2001.
Such initiatives encourage routine testing and facilitate early treatment, particularly in high-risk groups such as adolescents, sexually active young adults, and marginalized populations. These efforts significantly enhance market penetration and support the adoption of advanced diagnostic technologies.
Stigma and Lack of Awareness Remain Market Barriers
Despite favorable growth indicators, the CT/NG testing market faces several restraints. Social stigma, misinformation, and inadequate sexual health education continue to hinder the willingness of individuals to undergo STI testing. Cultural taboos and fear of judgment further contribute to the underutilization of testing services, particularly among adolescents and individuals in conservative regions.
These psychological and social barriers often result in underdiagnosis and delayed treatment, which not only impacts public health outcomes but also restricts the full market potential for CT/NG diagnostics globally.
Market Segmentation Insights
By Product Type
The assays & kits segment led the market with an 84.11% share in 2024. These products offer high accuracy and speed and are widely used in hospitals, diagnostic labs, and point-of-care (POC) settings. Their ability to simultaneously detect both CT and NG infections through multiplex assays makes them indispensable for large-scale screening.
The instruments/analyzers segment is expected to witness the fastest growth. Innovations in automated, portable, and high-throughput analyzers are making rapid diagnostics more accessible, thereby supporting timely treatment and infection control.
By Test Type
Laboratory testing remains the dominant segment with an 89.5% market share. Centralized testing using NAATs is considered the gold standard due to its high specificity and sensitivity, particularly in high-volume screening and diagnostic programs.
On the other hand, Point-of-Care (POC) testing is poised for rapid growth as the demand for decentralized healthcare, faster turnaround times, and accessible diagnostics continues to rise. These tests offer significant advantages in resource-limited settings and emergency response scenarios.
By Technology
Polymerase Chain Reaction (PCR) technology accounted for 68.06% of the market in 2024. PCR-based diagnostics enable early detection even with minimal bacterial load, thereby playing a vital role in infection control and epidemiological surveillance.
Emerging isothermal nucleic acid amplification technologies are projected to experience the highest growth during the forecast period. These platforms offer affordable, portable, and rapid testing solutions suitable for remote and under-resourced healthcare environments, making them ideal for global screening campaigns.
By End-Use
Diagnostic laboratories held the largest market share of 56.8% in 2024, thanks to their capacity for high-throughput testing, trained personnel, and robust infrastructure. These labs support national surveillance programs and are pivotal in population-level screening.
Hospitals and clinics are expected to grow at the fastest rate due to increasing demand for immediate and on-site diagnostics. Integration of molecular platforms into routine clinical workflows has streamlined patient care and treatment planning, further enhancing adoption in healthcare institutions.
Regional Market Landscape
North America
North America dominated the CT/NG testing market with a 38.60% share in 2024. The U.S. market alone was valued at USD 0.43 billion in 2024 and is projected to grow to USD 0.80 billion by 2032. Key growth drivers include robust diagnostic infrastructure, government-led testing programs, and high disease awareness among the population. The widespread use of NAATs and comprehensive reimbursement policies also contribute to this region’s leadership.
Asia Pacific
Asia Pacific is the fastest-growing region with a forecasted CAGR of 7.45%. The surge in urbanization, changing sexual behaviors, and increasing STI prevalence are major factors driving market expansion. Countries like China and India are investing heavily in public health infrastructure, with growing emphasis on affordable and accessible point-of-care testing.
Europe
The European CT/NG testing market is thriving due to well-organized national screening programs and unified regulatory frameworks. Public health strategies in countries like the UK have successfully improved STI testing rates, while the broader European region benefits from integrated sexual health education and streamlined diagnostics adoption.
Latin America and MEA
Latin America is experiencing gradual growth driven by urban public health initiatives and rising STI awareness. However, challenges such as fragmented healthcare systems and limited infrastructure persist.
The Middle East and Africa (MEA) region sees moderate progress. Governments and international health organizations are rolling out STI diagnostics and awareness programs, but sociocultural barriers and resource limitations continue to hinder broader market penetration.
Buy a Single-User PDF of CT/NG Testing Market Analysis & Outlook Report 2024-7454 @ https://www.snsinsider.com/checkout/7454
Competitive Landscape and Innovations
Key players in the CT/NG testing market include Abbott Laboratories, Becton, Dickinson & Company, Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Siemens Healthineers, Bio-Rad Laboratories, and Binx Health.
In January 2024, Qiagen N.V. received FDA clearance for its NeuMoDx CT/NG Assay 2.0, enhancing the speed and accessibility of STI diagnostics through its integrated PCR testing systems. Similarly, Bio-Rad Laboratories introduced new molecular quality controls for CT/NG testing to boost laboratory accuracy and reliability.
The CT/NG testing market is positioned for steady and significant growth over the coming years, underpinned by escalating STI rates, technological innovation in molecular diagnostics, and increased public health investments. As global healthcare systems strive for earlier detection, better accessibility, and more effective treatment strategies, the demand for reliable CT/NG testing solutions is expected to rise correspondingly. Strategic investments in awareness, decentralization, and diagnostic innovation will be essential for unlocking the full market potential and improving sexual health outcomes worldwide.
Read Our Other Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
